Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2015 2
2017 1
2018 1
2019 1
2020 3
2021 3
2022 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Suppression of malignant rhabdoid tumors through Chb-M'-mediated RUNX1 inhibition.
Daifu T, Mikami M, Hiramatsu H, Iwai A, Umeda K, Noura M, Kubota H, Masuda T, Furuichi K, Takasaki S, Noguchi Y, Morita K, Bando T, Hirata M, Kataoka TR, Nakahata T, Kuwahara Y, Iehara T, Hosoi H, Takita J, Sugiyama H, Adachi S, Kamikubo Y. Daifu T, et al. Among authors: masuda t. Pediatr Blood Cancer. 2021 Feb;68(2):e28789. doi: 10.1002/pbc.28789. Epub 2020 Nov 12. Pediatr Blood Cancer. 2021. PMID: 33180377
RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors.
Mikami M, Masuda T, Kanatani T, Noura M, Umeda K, Hiramatsu H, Kubota H, Daifu T, Iwai A, Hattori EY, Furuichi K, Takasaki S, Tanaka S, Matsui Y, Matsuo H, Hirata M, Kataoka TR, Nakahata T, Kuwahara Y, Iehara T, Hosoi H, Imai Y, Takita J, Sugiyama H, Adachi S, Kamikubo Y. Mikami M, et al. Among authors: masuda t. Mol Cells. 2022 Dec 31;45(12):886-895. doi: 10.14348/molcells.2022.2031. Epub 2022 Dec 12. Mol Cells. 2022. PMID: 36572559 Free PMC article.
RUNX inhibitor suppresses graft-versus-host disease through targeting RUNX-NFATC2 axis.
Kubota H, Masuda T, Noura M, Furuichi K, Matsuo H, Hirata M, Kataoka TR, Hiramatsu H, Yasumi T, Nakahata T, Imai Y, Takita J, Adachi S, Sugiyama H, Kamikubo Y. Kubota H, et al. Among authors: masuda t. EJHaem. 2021 May 19;2(3):449-458. doi: 10.1002/jha2.230. eCollection 2021 Aug. EJHaem. 2021. PMID: 35844683 Free PMC article.
RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Masuda T, Maeda S, Shimada S, Sakuramoto N, Morita K, Koyama A, Suzuki K, Mitsuda Y, Matsuo H, Kubota H, Kato I, Tanaka K, Takita J, Hirata M, Kataoka TR, Nakahata T, Adachi S, Hirai H, Mizuta S, Naka K, Imai Y, Kimura S, Sugiyama H, Kamikubo Y. Masuda T, et al. Cancer Sci. 2022 Feb;113(2):529-539. doi: 10.1111/cas.15239. Epub 2021 Dec 28. Cancer Sci. 2022. PMID: 34902205 Free PMC article.
Author Correction: A RUNX-targeted gene switch-off approach modulates the BIRC5/PIF1-p21 pathway and reduces glioblastoma growth in mice.
Hattori EY, Masuda T, Mineharu Y, Mikami M, Terada Y, Matsui Y, Kubota H, Matsuo H, Hirata M, Kataoka TR, Nakahata T, Ikeda S, Miyamoto S, Sugiyama H, Arakawa Y, Kamikubo Y. Hattori EY, et al. Among authors: masuda t. Commun Biol. 2022 Sep 27;5(1):1021. doi: 10.1038/s42003-022-04006-3. Commun Biol. 2022. PMID: 36167902 Free PMC article. No abstract available.
14 results